Terms: = Sarcomas AND HIST1H3B, H3_1, P68431, H3FJ, H3/j, H3FF, H3/f, H3_f, H3FK, H3F1K, H3/k, H3FH, H3/h, H3FI, H3/i, H3FD, H3/d, H3FB, H3/b, H3FC, H3/c, H3FL, H3/l, H3FA, H3/A, ENSG00000124693, 8358
13 results:
1. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract] [Full Text] [Related]
2. Identification of Serum miR-337-3p, miR-484, miR-582, and miR-3677 as Promising Biomarkers for Osteosarcoma.
Luo H; Ye Z
Clin Lab; 2021 Apr; 67(4):. PubMed ID: 33865271
[TBL] [Abstract] [Full Text] [Related]
3. Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy.
Snuderl M; Dolgalev I; Heguy A; Walsh MF; Benayed R; Jungbluth AA; Ladanyi M; Karajannis MA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31645348
[TBL] [Abstract] [Full Text] [Related]
4. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract] [Full Text] [Related]
5. HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
La Noce M; Paino F; Mele L; Papaccio G; Regad T; Lombardi A; Papaccio F; Desiderio V; Tirino V
J Exp Clin Cancer Res; 2018 Dec; 37(1):296. PubMed ID: 30509303
[TBL] [Abstract] [Full Text] [Related]
6. Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.
Ohshima K; Hatakeyama K; Nagashima T; Watanabe Y; Kanto K; Doi Y; Ide T; Shimoda Y; Tanabe T; Ohnami S; Ohnami S; Serizawa M; Maruyama K; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Sci Rep; 2017 Apr; 7(1):641. PubMed ID: 28377632
[TBL] [Abstract] [Full Text] [Related]
7. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
Lu C; Jain SU; Hoelper D; Bechet D; Molden RC; Ran L; Murphy D; Venneti S; Hameed M; Pawel BR; Wunder JS; Dickson BC; Lundgren SM; Jani KS; De Jay N; Papillon-Cavanagh S; Andrulis IL; Sawyer SL; Grynspan D; Turcotte RE; Nadaf J; Fahiminiyah S; Muir TW; Majewski J; Thompson CB; Chi P; Garcia BA; Allis CD; Jabado N; Lewis PW
Science; 2016 May; 352(6287):844-9. PubMed ID: 27174990
[TBL] [Abstract] [Full Text] [Related]
8. A loss of FUS/TLS function leads to impaired cellular proliferation.
Ward CL; Boggio KJ; Johnson BN; Boyd JB; Douthwright S; Shaffer SA; Landers JE; Glicksman MA; Bosco DA
Cell Death Dis; 2014 Dec; 5(12):e1572. PubMed ID: 25501833
[TBL] [Abstract] [Full Text] [Related]
9. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract] [Full Text] [Related]
10. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
[TBL] [Abstract] [Full Text] [Related]
11. The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Sampson ER; Amin V; Schwarz EM; O'Keefe RJ; Rosier RN
J Orthop Res; 2011 Apr; 29(4):623-32. PubMed ID: 20957741
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors.
Xu H; Cheung IY; Guo HF; Cheung NK
Cancer Res; 2009 Aug; 69(15):6275-81. PubMed ID: 19584290
[TBL] [Abstract] [Full Text] [Related]
13. Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions.
Waschbisch A; Wintterle S; Lochmüller H; Walter MC; Wischhusen J; Kieseier BC; Wiendl H
Arthritis Rheum; 2008 Nov; 58(11):3600-8. PubMed ID: 18975328
[TBL] [Abstract] [Full Text] [Related]
